Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like attention is trickling in, little by little. Nice initial move today.
We'll see, just depends on what the rules are (ie minimum MC etc.), but I think it's definetly possible.
Personally, I don't think there is any reason with the valuations in the other space companies that currently exist that the base here shouldn't at least be in that $100 million MC range. Double where it is now.
If Momentus is valued at a base at $1.2 Billion, ACCMF should at least be at that $100 Million level IMO. And I still feel that is being conservative. It is the only one when compared to SPCE, SRAC, NPA etc. that is projecting to be profitable by end of year.
I agree, sector definetly picking up. I wonder whether announcement of that new ETF and the huge surge in other space related stocks will start to trickle over to ACCMF. Just a matter of time.
If ETF were to ever add ACC Clyde Space to index as constituent company this would explode. I think it's certainly possible with the limited number of pure space plays that exist globally.
Yup, rightfully getting attention on the home exchange. Significantly undervalued IMO compared to peers. If $SRAC is valued at $1.2 Billion and they are still starting missions up and $ACC has a market cap in the $50-60 million range and has been running missions for quite a while along with the many other things we know it does makes you wonder. At some point IMO this has 10x-20x potential. For it to build massive gains I think they will need more awareness and ideally listing on one of the major exchanges.
What I am really hoping is they start to build out that board of directors to reflect bigger names in aerospace. Beyond joining OTCQB, the acquisitions and the contracts, I think that is a good next step on building their brand more globally and attract legitimate institutional eyes in the way others are (ie Momentus).
Yup, no attention, although some building now. Very much flew under the radar when they listed on OTCQB the other month. Also first company dual listed from the Swedish exchange I believe which may have had something to do with no one noticing. Either way, early days for this one, been starting to accumulate and will continue to as part of a macro play.
Can they get their story in front of investors well enough not having their main listing on any major exchange and make aggressive enough moves to quickly build market share? Looking forward to watching this the next couple years.
I agree, will be an interesting one to watch play out. I know some of the SRAC investors are eyeing this as well. At ~$50 million US market cap, if attention comes here and there are continued moves from SPCE & SRAC, along with successful launches and renewed attention in space (driven by high profile names e.g. Musk etc.) there are only a few places for American investor dollars to flow as a pure space play.
The question I have is as with many foreign listed OTC stocks usually they tend to follow the lead of stock performance where it is listed (ie Swedish exchange). However, I could see the potential here for the reverse to happen if American investors pile in, where the OTC price starts to lead performance on Nasdaq Stockholm.
We'll see, but with Momentus being priced as a $1.2 billion dollar company and with a comparatively low market cap and some great news and updates from company in the last month,
great potential for a very large move IMO.
One of the only pure space plays in the US Markets, just listed on OTCQB and just announced a $22.5 million contract with European Space Agency and UK Space Agency. We'll see how it evolves, but its a nice market and while speculative, they are already bringing in income.
They have expressed interest in expansion into US Market, and last month made moves with OTCQB listing and acquisition of Virginia based SpaceQuest. They are moving fast and aggressively. Besides $SPCE and upcoming $SRAC merger with Momentus it is the only pure legitimate space play that I know of. Watching closely.
https://news.satnews.com/2020/11/20/aac-clyde-space-now-engaged-in-new-constellation-services-with-esa-uk-space-agency/
Looks like it was done on June 2nd. Someone lucked into cheap shares at $.87. I wish I could go back in time to load up at those prices. Such positive moves lately, cleaning things up, bringing in the JNJ people etc. Getting ready for what's about to happen.
Getting shares not easy on this one without hitting the ask. Prime mover potential once it hits the big boards.
I think you are spot on and you've been screaming from the mountain top which I appreciate. Always one of my favorite DD'ers back when I was on here alot.
Just bought more at HOD which I rarely ever do and am 100% ok with, a ton more room to move on the sequence of events happening here with the virus, with government funding and with the company and lenzuilumab itself. Combined with uplisting to the NASDAQ and the volume and attention that will bring in with retail (ie stocktwits, robinhood) a no brainer to me at least.
First Post on Ihub in 5 years. HGEN has me out of my slumber. Nice find and DD MWM & team.
Trading Halt on ASX. Potentially big news on Boda Prospect on the way. Looks like trading on OTC in anticipation.
https://www.proactiveinvestors.com.au/companies/amp/news/912710
The interest appears to be growing, but still under the radar. Recent filings seem to be showing funds are adding recently. Feel good on the potential and at these levels.
Solid Conference Call and Projections.
On Kaletra glad that they didn't take advantage of the Coronavirus fears to hype anything on that call or put out bogus press release etc. They very much downplayed and expressed thoughts with the families of those affected, the way it should be.
Here's the latest on Kaletra usage at the moment. It's giving some people hope, whether it works or not is another story. Hope one of the drugs helps, whether Kaletra or the GILD drug etc.
https://mobile.reuters.com/article/amp/idUSKBN2000HA
Yeah, interesting activity on the options market too. We'll see what happens.
Yup, there with you. I truly hope for everyone's sake it at least can give some hope in increasingly difficult to control epidemic.
Some day soon I am pretty sure investors will start putting money into treatment options, versus bogus penny plays or stocks with products that may or may not be effective with coronavirus. LCI, ABBV and GILD all appear to have products with positive real world implications now.
Food for thought, latest study out on effectiveness of thermal detection on the coronavirus at airports. Definetly a case to be made for better diagnostics on detection.
https://www.lshtm.ac.uk/newsevents/news/2020/how-effective-thermal-scanning-airports
Also, not sure what the hold up is at the CDC, but there are alot of samples that have not yet been run it appears. Potentially won'tsee results in San Diego until the weekend. Seems pretty long for a major city no?
San Diego County's still waiting for test results on possible coronavirus case - The San Diego Union-Tribune #SmartNews https://t.co/kn4MbsnUvh
— gary j (@garyjholliday3) January 29, 2020
More on the lopinavir/ritonavir coronavirus treatment they are currently using.
https://interestingengineering.com/using-an-anti-hiv-combination-or-other-medical-drugs-could-combat-the-coronavirus
Looks positive so far, previously showed positive clinical outcomes when tried with SARS and appears to here as well. Hopefully will be the case here and gives some hope to the more severe cases.
Maybe they will give some comment or thoughts about that on conference call?
$LCI completely unnoticed coronavirus stock. They make the generic for Kaletra by Abbvie, which is the one of the few drugs being used as part of the current treatment regimen in China and it appears to have shown effectiveness on the virus. Wanted to put on people's radar. Hopefully this drug will help the situation.
https://www.bloomberg.com/news/articles/2020-01-26/china-names-abbvie-s-hiv-drugs-in-treatment-plan-for-new-virus
http://news.cnhubei.com/content/2020-01/28/content_12656365.html
$LCI completely unnoticed coronavirus stock. They make the generic for Kaletra by Abbvie, which is the one of the few drugs being used as part of the current treatment regimen in China and it appears to have shown effectiveness on the virus. Wanted to put on people's radar. Hopefully this drug will help the situation.
https://www.bloomberg.com/news/articles/2020-01-26/china-names-abbvie-s-hiv-drugs-in-treatment-plan-for-new-virus
http://news.cnhubei.com/content/2020-01/28/content_12656365.html
Ritonavir being used as part of current coronavirus treatment regimen in China. From discussion yesterday: http://news.cnhubei.com/content/2020-01/28/content_12656365.html
Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus
Release time: January 28, 2020 23:38 Source: Hubei Daily
Hubei Daily (Reporter Wen Jun, correspondent Long Hua, Hu Shuwei) On January 28, a series of good news came out from the Wuhan Institute of Virology, Chinese Academy of Sciences: The institute has just developed antibody test strips for research; The Institute and the Institute of Toxicology and Drugs of the Academy of Military Medical Sciences have jointly found Remdesivir or Remdesivir (GS-5734), chloroquine (Remdesivir (GS-5734), chloroquine ( Chloroquine, Sigma-C6628), Ritonavir and three other "old drugs". Its subsequent clinical use is undergoing related procedures for approval.
In the past few days, relevant departments and scientific research units of the scientific and technological circles in our province have stepped up scientific and technological research and development, highlighted the urgent need for prevention and control, gave full play to the role of experts, and endeavored to provide scientific and technological support for front-line prevention and control treatment. Ning Qin, chief physician of the Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, pointed out that most patients with pneumonitis infected by new coronavirus have a good prognosis and a few patients are critically ill; symptoms of children are relatively mild, and the elderly and those with basic diseases are infected. Heavier. Based on current epidemiological investigations, the incubation period of the virus is 3-7 days, with a maximum of 14 days. She believes that in view of the similarities between the new coronavirus and SARS-Cov virus and their clinical symptoms, it is speculated that the pathogenic mechanism is likely to be caused by the activation of the body's autoimmune attack on autologous lungs and immune organs, but the specific mechanism uncertain.
On January 21, according to the urgent scientific and technological needs of rapid epidemic disposal and emergency response, the Provincial Department of Science and Technology launched the "2019 New Pneumonia Emergency Science and Technology Research Project", established a new type of pneumonia emergency scientific research research expert group, and quickly promoted related research work. The Scientific Research Group of the Pneumonia Prevention and Control Headquarters of Hubei Province New Coronavirus Infection organized a strong team in the province in several related fields such as virology and epidemiology, led by the Wuhan Institute of Virology of the Chinese Academy of Sciences, focusing on "rapid detection technology products" Emergency research has been initiated in five areas, including R & D, the law of disease occurrence, development, and outcome, and clinical diagnosis and treatment, antiviral emergency drugs and vaccines, animal traceability research, and etiology and epidemiology research. With a view to carrying out epidemiological investigation and etiology traceability as soon as possible, revealing the mechanisms and rules of inflammatory response caused by pathogen infection as soon as possible, providing the foundation for disease treatment and drug development as soon as possible, and forming the ability to quickly detect and respond to new-type coronavirus as soon as possible. At present, the Ministry of Science and Technology is organizing scientific and technological research on the diagnosis and treatment of new pneumonia. The emergency science and technology research project initiated by Hubei Province is very timely. The scientific research and research system on the diagnosis and treatment of new pneumonia has been formed with the emergency research on new pneumonia diagnosis and treatment carried out by the Ministry of Science and Technology.
Wu Tangchun, dean and professor of the School of Public Health of Tongji Medical College of Huazhong University of Science and Technology, believes that the highest priority and most effective prevention and control strategy is still to control the source of infection and cut off the transmission route. Monitoring and screening of hospitals and crowded places should be strengthened, medical institutions at all levels should be urged to report cases and suspected cases in a timely manner, strengthen the training of medical and health technicians, and improve the ability of early identification and diagnosis of cases. It is necessary to implement centralized centralized treatment of cases And suspected cases and treated in isolation. Considering the source of infection, the effectiveness of treatment, and the mortality rate, suggestions for encouraging mild and moderate suspected patients to be isolated and treated at home should be supported instead of waiting in line at the hospital.
Professor Tongchun Chun also believes that because the transmission of new coronavirus pneumonia is still not completely clear, drawing on the main prevention and control experience of respiratory infectious diseases, it is recommended to cut off the transmission through strengthening disinfection, ventilation, personal protection and other means, and to strengthen the tracking of close contacts, Detection, isolation and protection. The public must treat the epidemic rationally without panic.
I agree, it's an awful situation. Hopefully LCI can help fill a void. And if news is that lopinavir-ritonavir actually works here that would be huge on treatment.
I can’t confirm this but heard they were using #kaletra aka (lopinavir-ritonavir) as one of the antivirals. If that’s the case it’s great to see all of the investment into #HIV having other uses. #nCoV2019 https://t.co/wk8DeOwCUw
— Krutika Kuppalli, MD FIDSA (@KrutikaKuppalli) January 28, 2020
Yeah, I agree. If the number of cases grows then eventually Lannett will be needed and not by giveaway. Imagining supply of the drug will be stretched. Stumbled on LCI and wondered with all the other biotechs spiking, the only one that is producing a drug that is currently being used as treatment is not. Same so far with Abbvie, I think with giveaway like Gilead they are sending to test and see if it works.
Yeah, not sure investors have made the connection yet to the coronavirus treatment. Off the radar, we'll see what happens.
Don't know much on LCI, but surprised that it hasn't moved up like the other Coronavirus related stocks. Any idea why?
As far as I can see, they are producing the generic of Abbvie's Kaletra which is currently being used as part of the treatment regimen for the Coronavirus. . But, don't much about the company overall, so curious on thoughts?
https://www.fiercepharma.com/pharma-asia/china-repurposes-abbvie-hiv-dug-as-big-pharma-rallies-to-help-combat-deadly-coronavirus
Looks like just delisted ADR (ANLKY), not common (ALKEF)? Strange, company in an extremely bullish place at the moment.
Yeah, been watching that one too. Nothing much there yet, we'll see. Odd activity. The REEMF movement was very parallel to the volume coming into LYSDY. Both started right around 10-1015.
Also sudden volume and move up in LYSDY which is interesting, but not every rare earth moving, so doesn't look like broad rare earth market yet and no news that I see...hmmm...
I'm going to put a bid in, way oversold In this range IMO. Strong support in historical chart at this level. Rollout may not have played out exactly right, but legit company, strong assets etc. And self off on low volume.
.70 way too cheap here IMO, feels like a panic selling situation? No reason this should be anywhere under $1. The fact they are getting filings up and who knows if we might see some more buys here from Newman or others. Very thin in the way back up, just needs a little push and could easily be back up at $2+ quickly.
Up and up it goes since the RM...nice movement.
Yeah, I believe it should have been out by now too. That said in looking at the 10-K and 40-17G this is the first quarter where they have to integrate all that, pretty mammoth task. We'll see what happens, but atm still feel like it should be happening soon per what they indicated in the late filing notice.
Statute of limitations? I didn't realize something from so long ago (70 years) under previous entity could still have liability today. Although, still not sure I understand what the case may be here.
Wow, now that's out of left field.
Yeah, would have been the dream scenario :) But, total longshot, still nice to have him associated.
I did, the same exact day as this filing...what is he up to?
Form 15 I mean
Might be going way of LINK where they stop filing, filed a form 25, but still are OTC Pink Current? That would fit what he did previously although why then did he never do with FNSI or RDGA?